Drug Trial Radar · NCT05776927
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Aug 4, 2026
Primary completion
Dec 30, 2028
Study completion Jan 30, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of indacaterol acetate / glycopyrronium bromide / mometasone furoate (QVM149) compared to salmeterol xinafoate / fluticasone propionate in children from 12 to less than 18 years of age with asthma with pre-bronchodilator FEV1 ≥ 50 % of the predicted normal value for the participant.
Conditions
- Asthma
Interventions
QVM149Drug
QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg once daily delivered via Breezhaler®
Salmeterol Xinafoate / Fluticasone PropionateDrug
Salmeterol xinafoate 50 μg / fluticasone propionate 500 μg twice daily delivered via Girohaler®
Placebo to QVM149Drug
Placebo to QVM149 150/50/160 µg once daily delivered via Breezhaler®
Placebo to salmeterol xinafoate / fluticasone propionateDrug
Placebo to salmeterol xinafoate/fluticasone propionate 50/500 μg twice daily delivered via Girohaler®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Trough FEV1Time frame: Baseline, Week 12 of each treatment period.
Locations
27 sites in 10 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina · Recruiting
Novartis Investigative Site
Strasbourg, France · Recruiting
Novartis Investigative Site
Bielefeld, Germany · Recruiting
Novartis Investigative Site
Wesel, North Rhine-Westphalia, Germany · Recruiting
Novartis Investigative Site
Szeged, Hungary · Recruiting
Novartis Investigative Site
Bialystok, Poland · Recruiting
Novartis Investigative Site
Krakow, Poland · Recruiting
Novartis Investigative Site
Lublin, Poland · Recruiting
Novartis Investigative Site
Piaseczno, Poland · Recruiting
Novartis Investigative Site
Torun, Poland · Recruiting
Novartis Investigative Site
Tarnów, Poland, Poland · Recruiting
Novartis Investigative Site
Bucharest, Romania · Recruiting
Novartis Investigative Site
Banská Bystrica, Slovakia · Recruiting
Novartis Investigative Site
Bratislava, Slovakia · Recruiting
Novartis Investigative Site
Košice, Slovakia · Recruiting
Novartis Investigative Site
Bratislava, Mestska Cast Ruzinov, Slovakia · Recruiting
Novartis Investigative Site
Cape Town, South Africa · Recruiting
Novartis Investigative Site
Pretoria, South Africa · Recruiting
Novartis Investigative Site
East London, Eastern Cape, South Africa · Recruiting
Novartis Investigative Site
Germiston, Gauteng, South Africa · Recruiting
Novartis Investigative Site
Krugersdorp, Gauteng, South Africa · Recruiting
Novartis Investigative Site
Lenasia, Gauteng, South Africa · Recruiting
Novartis Investigative Site
Paarl, Western Cape, South Africa · Recruiting
Novartis Investigative Site
Seville, Spain · Recruiting
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain · Recruiting
Novartis Investigative Site
Sabadell, Barcelona, Spain · Recruiting
Novartis Investigative Site
Kaohsiung City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.